Table 1

Demographic, clinical and laboratory characteristics for patients at baseline and at the 3-month visit (time for randomisation)

Treatment A (n = 22)

Treatment B (n = 18)

Baseline

Age (years)

59.5 (58.0 to 67.0)

56.0 (42.0 to 73.0)

Women

16 (73%)

13 (72%)

Menopause

14 (88%)

8 (62%)

Current or previous smoker

15(68%)

7 (41%)

Disease duration (months)

5.4 (2.9)

4.9 (3.4)

Rheumatoid factor positivity

11 (50%)

10 (56%)

X-ray criteria at baseline

7 (32%)

2 (11%)

3-month visit

Erythrocyte sedimentation rate (mm)

25.0 (14.0 to 29.0)

23.5 (12.0 to 34.0)

Disease Activity Score of 28 joints

4.3 (4.1 to 4.9)

4.8 (3.7 to 5.1)

HAQ score

0.86 (0.50)

0.89 (0.18)

Leptin (μg/l)

8.8 (5.4 to 27.7)

7.9 (3.9 to 14.2)

Adiponectin (mg/l)

10.7 (3.4)

10.9 (6.6)

Apolipoprotein A1 (g/l)

1.46 (0.25)

1.64 (0.23)

Apolipoprotein B (g/l)

1.10 (0.26)

1.03 (0.21)

Apolipoprotein B/apolipoprotein A1

0.77 (0.24)

0.64 (0.15)

P1NP (μg/l)

46 (36 to 58)

43 (32 to 68)

CTX-1 (pg/ml)

280 (191 to 368)

233 (119 to 457)

1CTP (μg/l)

4.1 (3.3 to 5.6)

3.7 (2.9 to 4.9)

IGF-1 (μg/l)

145.5 (114.0 to 166.0)

154.5 (130.0 to 193.0)

IGF-1 SD scores

-0.09 (1.34)

-0.07 (-0.12)

Demographic, clinical and laboratory characteristics at baseline and at the 3-month visit (time for randomisation). Data presented as median (interquartile range), n (%) or mean (standard deviation (SD)). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate + infliximab. HAQ, Health Assessment Questionnaire, P1NP, procollagen type I N-terminal propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal propeptide of type I collagen; IGF-1, insulin-like growth factor-1.

Engvall et al. Arthritis Research & Therapy 2010 12:R197   doi:10.1186/ar3169